{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:19:27Z","timestamp":1779909567897,"version":"3.53.1"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>The introduction of antiretroviral therapy (ART) has significantly prolonged the lifespan of people living with human immunodeficiency virus (PLWH). However, the sustained use of this drug regimen has also been associated with a cluster of metabolic anomalies, including renal toxicity, which can lead to the development of kidney diseases. In this study, we reviewed studies examining kidney disease in PLWH sourced from electronic databases such as PubMed\/MEDLINE, Scopus, and Google Scholar, as well as gray literature. The narrative synthesis of data from these clinical studies demonstrated that the serum levels of cystatin C remained unchanged or were not affected in PLWH on ART, while the creatinine-based glomerular filtration rate (GFR) fluctuated. In fact, some of the included studies showed that the creatinine-based GFR was increased in PLWH taking tenofovir disoproxil fumarate-containing ART, perhaps indicating that the use of both cystatin C- and creatinine-based GFRs is vital to monitor the development of kidney disease in PLWH. Clinical data summarized within this study indicate the potential detrimental effects of tenofovir-based ART regimens in causing renal tubular injury, while highlighting the possible beneficial effects of dolutegravir-based ART on improving the kidney function in PLWH. However, the summarized literature remains limited, while further clinical studies are required to provide insights into the potential use of cystatin C as a biomarker for kidney disease in PLWH.<\/jats:p>","DOI":"10.3389\/fmed.2024.1295217","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T04:24:13Z","timestamp":1710822253000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["A systematic review assessing the potential use of cystatin c as a biomarker for kidney disease in people living with HIV on antiretroviral therapy"],"prefix":"10.3389","volume":"11","author":[{"given":"Sidney","family":"Hanser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Choshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haskly","family":"Mokoena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihle E.","family":"Mabhida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zandile J. R.","family":"Mchiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marakiya T.","family":"Moetlediwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ndivhuwo","family":"Muvhulawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bongani B.","family":"Nkambule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duduzile","family":"Ndwandwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unati","family":"Nqebelele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 P.","family":"Kengne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phiwayinkosi V.","family":"Dludla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12882-023-03109-1","article-title":"The prevalence of chronic kidney disease in South Africa\u2014limitations of studies comparing prevalence with sub-Saharan Africa, Africa, and globally","volume":"24","author":"Hariparshad","year":"2023","journal-title":"BMC Nephrol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3390\/jcm8081254","article-title":"Kidney disease in HIV infection","volume":"8","author":"Alfano","year":"2019","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.nephro.2016.02.005","article-title":"Acute kidney injury and chronic kidney disease: from the laboratory to the clinic","volume":"12","author":"Ferenbach","year":"2016","journal-title":"Nephrol Ther"},{"key":"ref5","first-page":"85","article-title":"Acute kidney injury: definition, pathophysiology and clinical phenotypes","volume":"37","author":"Makris","year":"2016","journal-title":"Clin Biochem Rev"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1097\/QAI.0000000000002698","article-title":"Brief report: acute kidney injury in people living with HIV hospitalized with coronavirus disease 2019: clinical characteristics and outcomes","volume":"87","author":"Fisher","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000337151","article-title":"Incidence and risk factors for acute kidney injury in HIV infection","volume":"35","author":"Li","year":"2012","journal-title":"Am J Nephrol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e068672","DOI":"10.1136\/bmjopen-2022-068672","article-title":"Leveraging the south African diabetes prevention Programme to screen for chronic kidney disease: an observational study","volume":"13","author":"George","year":"2023","journal-title":"BMJ Open"},{"key":"ref9","first-page":"229","article-title":"Adverse effects of antiretroviral therapy for HIV infection","volume":"170","author":"Montessori","year":"2004","journal-title":"CMAJ"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/hiv.12733","article-title":"Adverse effects of chronic treatment with the Main subclasses of highly active antiretroviral therapy: a systematic review","volume":"20","author":"Silva","year":"2019","journal-title":"HIV Med"},{"key":"ref11","first-page":"13","article-title":"Kidney disease and HIV infection","volume":"25","author":"Wyatt","year":"2017","journal-title":"Top Antivir Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12882-019-1335-9","article-title":"Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting","volume":"20","author":"Kabor\u00e9","year":"2019","journal-title":"BMC Nephrol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.kint.2017.11.007","article-title":"Kidney disease in the setting of HIV infection: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"93","author":"Swanepoel","year":"2018","journal-title":"Kidney Int"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/HIV.S32321","article-title":"Quality of life of people living with HIV and AIDS and antiretroviral therapy","volume":"4","author":"Oguntibeju","year":"2012","journal-title":"HIV AIDS"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e0269260","DOI":"10.1371\/journal.pone.0269260","article-title":"Clinicopathological correlation of kidney disease in HIV infection pre- and post-ART rollout","volume":"17","author":"Diana","year":"2022","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/hiv.12087","article-title":"Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals","volume":"15","author":"Lucas","year":"2014","journal-title":"HIV Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jiac.2017.10.015","article-title":"Clinical benefits of using inulin clearance and cystatin C for determining glomerular filtration rate in HIV-1-infected individuals treated with dolutegravir","volume":"24","author":"Yukawa","year":"2018","journal-title":"J Infect Chemother"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12981-020-00266-3","article-title":"Contemporary issues and new challenges in chronic kidney disease amongst people living with HIV","volume":"17","author":"Heron","year":"2020","journal-title":"AIDS Res Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4103\/0971-4065.111840","article-title":"Serum cystatin C as a marker of renal function in detection of early acute kidney injury","volume":"23","author":"Murty","year":"2013","journal-title":"Indian J Nephrol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"348","DOI":"10.2215\/CJN.02870707","article-title":"Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C","volume":"3","author":"Baxmann","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref21","first-page":"776","article-title":"Chronic kidney disease: detection and evaluation","volume":"96","author":"Gaitonde","year":"2017","journal-title":"Am Fam Physician"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/MNH.0000000000000115","article-title":"Cystatin C as a biomarker for estimating glomerular filtration rate","volume":"24","author":"Ferguson","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/QAD.0000000000003434","article-title":"Cystatin C in addition to creatinine for better assessment of glomerular renal function decline in people with HIV receiving antiretroviral therapy","volume":"37","author":"Mondesert","year":"2023","journal-title":"AIDS"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/hiv.12784","article-title":"Evaluation of kidney function in HIV-infected patients receiving an antiretroviral regimen containing one or two inhibitors of the tubular secretion of creatinine","volume":"20","author":"Casado","year":"2019","journal-title":"HIV Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e027079","DOI":"10.1161\/JAHA.122.027079","article-title":"Differential associations of cystatin C versus creatinine-based kidney function with risks of cardiovascular event and mortality among south Asian individuals in the UK biobank","volume":"12","author":"Chen","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1093\/ndt\/gfs001","article-title":"Cystatin C in HIV-infected patients: promising but not yet ready for prime time","volume":"27","author":"Gagneux-Brunon","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/HIV.S120979","article-title":"Assessment of the effect of antiretroviral therapy on renal and liver functions among HIV-infected patients: a retrospective study","volume":"9","author":"Wondifraw Baynes","year":"2017","journal-title":"HIV AIDS"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1086\/503566","article-title":"HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy","volume":"42","author":"R\u00f6ling","year":"2006","journal-title":"Clin Infect Dis"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"Ed000142","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions","volume":"52","author":"Downs","year":"1998","journal-title":"J Epidemiol Community Health"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s13104-015-1181-1","article-title":"Failure of a numerical quality assessment scale to identify potential risk of bias in a systematic review: a comparison study","volume":"8","author":"O'Connor","year":"2015","journal-title":"BMC Res Notes"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1053\/j.ajkd.2008.01.027","article-title":"Cystatin C and creatinine in an HIV cohort: the nutrition for healthy living study","volume":"51","author":"Jones","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/135965350801300810","article-title":"Cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients","volume":"13","author":"Mauss","year":"2008","journal-title":"Antivir Ther"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2174\/157016210791330365","article-title":"Cystatin C, adipokines and cardiovascular risk in HIV infected patients","volume":"8","author":"Falasca","year":"2010","journal-title":"Curr HIV Res"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"P62","DOI":"10.1186\/1742-4690-7-S1-P62","article-title":"Cystatin C and cardiovascular risk in HIV infected patients","volume":"7","author":"Falasca","year":"2010","journal-title":"Retrovirology"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/QAI.0b013e31826a6c4f","article-title":"Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals","volume":"61","author":"Inker","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1089\/aid.2011.0018","article-title":"Cystatin C and baseline renal function among HIV-infected persons in the SUN study","volume":"28","author":"Overton","year":"2012","journal-title":"AIDS Res Hum Retrovir"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"e82028","DOI":"10.1371\/journal.pone.0082028","article-title":"HIV viremia and T-cell activation differentially affect the performance of glomerular filtration rate equations based on creatinine and cystatin C","volume":"8","author":"Bhasin","year":"2013","journal-title":"PLoS One"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1089\/aid.2017.0074","article-title":"Short communication: the clinical value of cystatin C as a marker of renal function in HIV patients receiving Dolutegravir","volume":"33","author":"Yoshino","year":"2017","journal-title":"AIDS Res Hum Retrovir"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/bcpt.12919","article-title":"Higher levels of cystatin C in HIV\/AIDS patients with metabolic syndrome","volume":"122","author":"Dragovi\u0107","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"236","DOI":"10.5114\/hivar.2018.80254","article-title":"Assessment of urinary cystatin C levels in HIV-1-infected patients with preserved kidney function","volume":"17","author":"Szymczak","year":"2018","journal-title":"HIV AIDS Rev"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/hiv.12819","article-title":"Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial","volume":"21","author":"Hamzah","year":"2020","journal-title":"HIV Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.36346\/sarjaf.2020.v02i04.003","article-title":"Study of cystatin C in early detection of renal impairment in patient with HIV\/AIDS","volume":"2","author":"Ikpeama Osita John","year":"2020","journal-title":"South Asian Res J Agri Fisher"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"132","DOI":"10.18231\/j.jchm.2021.030","article-title":"Evaluation of microalbumin, cystatin c, creatinine and uric acid levels in HIV patients in Nnamdi Azikiwe university teaching hospital, Nnewi","volume":"8","author":"Ezeugwunne Ifeoma Priscilla","year":"2021","journal-title":"J Commun Health Manage"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/15284336.2019.1608714","article-title":"Darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in treatment-na\u00efve patients with HIV-1: subgroup analyses of the phase 3 AMBER study","volume":"20","author":"Rashbaum","year":"2019","journal-title":"HIV Res Clin Pract"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"e26003","DOI":"10.1097\/MD.0000000000026003","article-title":"Estimation of renal function by three CKD-EPI equations in Chinese HIV\/AIDS patients: a STROBE-compliant article","volume":"100","author":"Zhao","year":"2021","journal-title":"Medicine"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jiac.2021.11.016","article-title":"Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on estimated glomerular filtration rate slope in patients with HIV: a retrospective observational study","volume":"28","author":"Hikasa","year":"2022","journal-title":"J Infect Chemother"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.2147\/IDR.S347054","article-title":"Comparison of renal function biomarkers of serum creatinine and cystatin C in HIV-infected people on Dolutegravir-containing therapy","volume":"15","author":"Lu","year":"2022","journal-title":"Infect Drug Resist"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/25787489.2021.2022825","article-title":"Switching to a NRTI-free 2 drug regimen (2DR) -a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes","volume":"23","author":"Monin","year":"2021","journal-title":"HIV Res Clin Pract"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"88","DOI":"10.14238\/pi63.2.2023.88-95","article-title":"Association of CD4 cell counts and viral load with cystatin C level in children with human immunodeficiency virus (HIV) infection","volume":"63","author":"Wita Rostania","year":"2023","journal-title":"Paediatr Indones"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13643-018-0927-y","article-title":"Prevalence of metabolic syndrome among HIV-positive and HIV-negative populations in sub-Saharan Africa-a systematic review and meta-analysis","volume":"8","author":"Todowede","year":"2019","journal-title":"Syst Rev"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"410","DOI":"10.4314\/ahs.v22i1.50","article-title":"Metabolic syndrome and its components among HIV\/AIDS patients on antiretroviral therapy and ART-Na\u00efve patients at the University of Calabar Teaching Hospital, Calabar, Nigeria","volume":"22","author":"Ojong","year":"2022","journal-title":"Afr Health Sci"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.24875\/AIDSRev.20000039","article-title":"The effect of successful antiretroviral therapy on immune activation and reconstitution in HIV infected adults: a systematic review and Meta-analysis","volume":"23","author":"Nyambuya","year":"2020","journal-title":"AIDS Rev"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s12916-020-01801-9","article-title":"Platelet activation in adult HIV-infected patients on antiretroviral therapy: a systematic review and meta-analysis","volume":"18","author":"Nkambule","year":"2020","journal-title":"BMC Med"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1155\/S1064744998000404","article-title":"Zidovudine","volume":"6","author":"Sperling","year":"1998","journal-title":"Infect Dis Obstet Gynecol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.4081\/idr.2013.s1.e2","article-title":"Recent developments in hiv treatment and their dissemination in poor countries","volume":"5","author":"Ebrahim","year":"2013","journal-title":"Infect Dis Rep"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"635089","DOI":"10.3389\/fphar.2021.635089","article-title":"HIV protease inhibitors and insulin sensitivity: a systematic review and Meta-analysis of randomized controlled trials","volume":"12","author":"Kajogoo","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12902-023-01340-3","article-title":"Metabolic syndrome among people living with HIV on antiretroviral therapy in Mwanza, Tanzania","volume":"23","author":"Malindisa","year":"2023","journal-title":"BMC Endocr Disord"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1097\/QAD.0b013e32832c96e9","article-title":"Renal function with use of a tenofovir-containing initial antiretroviral regimen","volume":"23","author":"Gallant","year":"2009","journal-title":"AIDS"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1681\/ASN.2012080857","article-title":"Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?","volume":"24","author":"Tourret","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"817","DOI":"10.4102\/sajhivmed.v19i1.817","article-title":"An overview of tenofovir and renal disease for the HIV-treating clinician","volume":"19","author":"Venter","year":"2018","journal-title":"South Afr J HIV Med"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.semnephrol.2008.08.008","article-title":"Acute kidney injury in HIV-infected patients","volume":"28","author":"Kalim","year":"2008","journal-title":"Semin Nephrol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12916-022-02438-6","article-title":"The need for screening, early diagnosis, and prediction of chronic kidney disease in people with diabetes in low- and middle-income countries-a review of the current literature","volume":"20","author":"George","year":"2022","journal-title":"BMC Med"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"e000256","DOI":"10.1136\/bmjgh-2016-000256","article-title":"Chronic kidney disease in low-income to middle-income countries: the case for increased screening","volume":"2","author":"George","year":"2017","journal-title":"BMJ Glob Health"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"79","DOI":"10.33176\/AACB-18-00017","article-title":"Kidney injury biomarkers in an academic hospital setting: where are we now?","volume":"40","author":"van Duijl","year":"2019","journal-title":"Clin Biochem Rev"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"e0211630","DOI":"10.1371\/journal.pone.0211630","article-title":"Serum creatinine and estimated glomerular filtration rates in HIV positive and negative adults in Ethiopia","volume":"14","author":"Yilma","year":"2019","journal-title":"PLoS One"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa2101609","article-title":"Dolutegravir or Darunavir in combination with zidovudine or Tenofovir to treat HIV","volume":"385","author":"Paton","year":"2021","journal-title":"N Engl J Med"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/2040622314530461","article-title":"Dolutegravir: clinical efficacy and role in HIV therapy","volume":"5","author":"Fantauzzi","year":"2014","journal-title":"Ther Adv Chronic Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1295217\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T15:17:41Z","timestamp":1731597461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1295217\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":68,"alternative-id":["10.3389\/fmed.2024.1295217"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1295217","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,19]]},"article-number":"1295217"}}